Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.17−0.27 (-4.96%)
Close on Nov 12, 2026Market cap $201.30MP/E –Yield –
Entrada Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Entrada Therapeutics's total assets was $266.88M at Sep 30, 2026. For fiscal 2025 it was $377.38M, down 28.3% from the year before. The highest annual figure on record is $526.32M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $377.38M | -28.3% |
| FY2024 | Dec 31, 2024 | $526.32M | +12.2% |
| FY2023 | Dec 31, 2023 | $469.19M | +86.1% |
| FY2022 | Dec 31, 2022 | $252.06M | -17.6% |
| FY2021 | Dec 31, 2021 | $305.83M | +602.6% |
| FY2020 | Dec 31, 2020 | $43.53M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $266.88M | -35.4% |
| Q2 FY2026 | Jun 30, 2026 | $298.88M | -33.4% |
| Q1 FY2026 | Mar 31, 2026 | $335.52M | -31.0% |
| Q4 FY2025 | Dec 31, 2025 | $377.38M | -28.3% |
| Q3 FY2025 | Sep 30, 2025 | $412.90M | -25.5% |
| Q2 FY2025 | Jun 30, 2025 | $448.78M | -22.9% |
| Q1 FY2025 | Mar 31, 2025 | $486.48M | -4.8% |
| Q4 FY2024 | Dec 31, 2024 | $526.32M | +12.2% |
| Q3 FY2024 | Sep 30, 2024 | $554.59M | +14.3% |
| Q2 FY2024 | Jun 30, 2024 | $581.96M | +17.8% |
| Q1 FY2024 | Mar 31, 2024 | $510.84M | +7.4% |
| Q4 FY2023 | Dec 31, 2023 | $469.19M | +86.1% |
| Q3 FY2023 | Sep 30, 2023 | $485.03M | +76.7% |
| Q2 FY2023 | Jun 30, 2023 | $493.98M | +66.9% |
| Q1 FY2023 | Mar 31, 2023 | $475.57M | +50.2% |
| Q4 FY2022 | Dec 31, 2022 | $252.06M | -17.6% |
| Q3 FY2022 | Sep 30, 2022 | $274.46M | +107.3% |
| Q2 FY2022 | Jun 30, 2022 | $295.92M | +579.8% |
| Q1 FY2022 | Mar 31, 2022 | $316.70M | – |
| Q4 FY2021 | Dec 31, 2021 | $305.83M | – |
| Q3 FY2021 | Sep 30, 2021 | $132.40M | – |
| Q4 FY2020 | Dec 31, 2020 | $43.53M | – |
See a number that looks wrong?